STATWho will pay for CRISPR?STATSpark Therapeutics of Philadelphia is vying to bring the first gene therapy to market in the U.S. to treat a rare genetic eye disease called Leber congenital amaurosis 2. Analysts said 5 it could cost a half-million doll… Continue reading
WhaTechStem Cell Therapy Market Trends, Growth and Opportunities by 2017-2022Medgadget (blog)This report studies the Global Stem Cell Therapy Market analyzes and researches the Stem Cell Therapy development status and forecast in United States, EU, Jap… Continue reading
Prostate cancer immunotherapy: the path forward.UroTodayDevelopment of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III l… Continue reading
Wall Street Journal (subscription)Crispr Offers a Leap Forward for Diagnosing DiseaseWall Street Journal (subscription)When it comes to treating deadly diseases, scientists are always looking for a method of diagnosis that is fast, cheap and accurate. … Continue reading
Wall Street Journal (subscription)Crispr Offers a Leap Forward for Diagnosing DiseaseWall Street Journal (subscription)When it comes to treating deadly diseases, scientists are always looking for a method of diagnosis that is fast, cheap and accurate. … Continue reading
|
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
UroToday Since the interferon trials for metastatic kidney cancer in the 1990’s, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in … |
UroToday |
CUA 2017: State of the Art Immunotherapy for Urologic Cancers.
UroToday Since the interferon trials for metastatic kidney cancer in the 1990’s, we have been waiting for subsequent immunotherapy breakthroughs. Over the past several years, we have certainly seen this with the targeting of immune checkpoints, first in … Now a cancer drug which avoids pain of chemotherapy?Deccan Chronicle |
FierceBiotech |
Novartis-backed GenSight gets cash for gene therapy launch
FierceBiotech GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials next year and … |